Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07271485 · ClinicalTrials.gov registry record · Early Phase 1
Propranolol for Misophonia
A Early Phase 1 study of Misophonia and Propanolol, sponsored by Bloom Mental Health.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT07271485: Recruiting Early Phase 1 study of Misophonia and Propanolol, sponsored by Bloom Mental Health.
NCT07271485 is a Early Phase 1 study of Misophonia and Propanolol that is actively recruiting participants, run by Bloom Mental Health. The registered enrollment target is 20 participants, below the 55-participant average among 7 other Misophonia trials with a reported enrollment target (64% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07271485, a Early Phase 1 study of Misophonia and Propanolol, is actively recruiting participants, sponsored by Bloom Mental Health.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary goal of this study is to investigate whether a one-time dose of 20 mg oral propranolol can temporarily reduce the adverse emotional and physical symptoms triggered by misophonia. The secondary goals of this study are: 1. Determine potential predictors of response to propranolol treatment, including demographic factors, baseline symptom severity, psychometric instrument item responses, and physiological characteristics. 2. Evaluate the safety and tolerability of propranolol in individuals with misophonia.
Primary Outcome
Heart rate was chosen as a primary biometric outcome because it reliably indicates sympathetic nervous system activation commonly observed in acute misophonia reactions. Given propranolol's established pharmacologic effect as a beta-blocker, the hypothesis is that propranolol will significantly blunt the heart rate increase typically elicited by misophonia triggers compared to placebo.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG propranolol
Study Locations (1)
Colorado
- Bloom Mental Health - Littleton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-12-19 |
| Est. Completion | 2026-12-19 |
| Phase | Early Phase 1 |
What NCT07271485 shows while recruiting
NCT07271485 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 55-participant average among 7 other Misophonia trials with a reported enrollment target (64% lower).
The record links to 3 conditions, with Misophonia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07271485 reports a single indexed study location in Colorado.
Frequently Asked Questions
What is clinical trial NCT07271485 about?
NCT07271485 is a clinical study titled "Propranolol for Misophonia". The primary goal of this study is to investigate whether a one-time dose of 20 mg oral propranolol can temporarily reduce the adverse emotional and physical symptoms triggered by misophonia. The secondary goals of this study are: 1. Determine potential predictors of response to propranolol treatme...
What is the current status of trial NCT07271485?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 20 participants. The study started on 2025-12-19. Estimated completion is 2026-12-19.
What conditions does trial NCT07271485 study?
This clinical trial studies the following conditions: Misophonia, Propanolol, Misophonia Treatment.
What interventions are being tested in trial NCT07271485?
The interventions under investigation include: Placebo (DRUG), propranolol (DRUG).
Who is sponsoring clinical trial NCT07271485?
This trial is sponsored by Bloom Mental Health, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07271485 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Misophonia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Using Neurostimulation to Accelerate Change in Misophonia: a Pilot Study
RECRUITING · NA
-
Transcranial Magnetic Stimulation in Misophonia
RECRUITING · NA
-
Mindfulness Application Effects on Mental Health Symptoms in Children With Severe Tinnitus and Misophonia
RECRUITING · NA
-
Digital Intervention for Adults With Misophonia: A Randomized Controlled Trial
RECRUITING · NA
-
Psychological Intervention for Misophonia
ACTIVE NOT RECRUITING · NA
-
Identifying the Optimal Neural Target for Misophonia Interventions
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI